Market Overview:
The global neuropeptide Y receptor type 2 market is expected to grow at a CAGR of xx% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of obesity, epilepsy, type 2 diabetes, and other diseases. Additionally, the increasing demand for novel therapies for the treatment of various diseases is also contributing to the growth of this market. The global neuropeptide Y receptor type 2 market can be segmented on the basis of type, application, and region. On the basis of type, this market can be segmented into XL-310, NN-9748 GT-002,, and others. On the basis of application,, this market can be divided into obesity,, epilepsy,,type 2 diabetes,,,,and others,. Geographically speaking,., followedby Europeand AsiaPacificregion.
Product Definition:
A neuropeptide Y receptor type 2 (NPY2) is a protein that in humans is encoded by the NPY2R gene.
XL-310:
Neuropeptide Y receptor type 2 is a protein that acts as an orphan G-protein coupled receptor. XL-310 is the trade name for a neuropeptide Y analog developed by Enzo Biochem Inc. in 2000.
NN-9748:
Neuropeptide Y receptor type 2 is a protein that in humans is encoded by the NPY2 gene. It belongs to the peptide family. Neuropeptide Y receptor type 2 plays an important role in modulating feeding behavior and energy homeostasis through neural pathways.
Application Insights:
The obesity segment dominated the global neuropeptide Y receptor type 2 market in terms of revenue in 2017. This is due to an increase in prevalence of obesity and a growing number of clinical trials supporting its use for weight management. The U.S., France, Germany, China and Italy are estimated to lead the application segment owing to high usage rates for various indications coupled with ongoing research activities across these countries.
Epilepsy is another significant application area where neuropeptide Y receptors are used therapeutically as it has been approved by the U.S FDA under investigational new drug category (IND) for this purpose only thus far; however, there is considerable interest from pharmaceutical companies regarding development of drugs based on NPY technology for epilepsy treatment outside United States as well as within it [17]. Other applications include diabetes mellitus type 2 and urinary incontinence among others [18].
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period. This can be attributed to extensive research and development undertaken by key companies for manufacturing peptide-based drugs, presence of well-established healthcare facilities, and high adoption of advanced technologies across this region. Moreover, increasing prevalence of obesity and diabetes has also led to an increase in demand for these products in North America over the past few years.
Asia Pacific is anticipated to witness lucrative growth during the same period owing to rising incidence of obesity coupled with growing disposable income among people living in emerging economies such as China & India & other Southeast Asian countries like Indonesia & Thailand etc.
Growth Factors:
- Increasing research and development activities by key players for the development of novel therapeutics for neuropeptide Y receptor type 2 market.
- Rising prevalence of neurological disorders such as anxiety, depression, obesity, and others is expected to fuel the demand for neuropeptide Y receptor type 2 drugs in the near future.
- Growing awareness about available treatment options for various neurological disorders is projected to boost the growth of neuropeptide Y receptor type 2 market during forecast period.
- Technological advancements in drug delivery systems are likely to offer lucrative opportunities for key players operating in neuropeptide Y receptor type 2 market over the next few years.
Scope Of The Report
Report Attributes
Report Details
Report Title
Neuropeptide Y Receptor Type 2 Market Research Report
By Type
XL-310, NN-9748, GT-002, Others
By Application
Obesity, Epilepsy, Type 2 Diabetes, Others
By Companies
Gila Therapeutics Inc, Novo Nordisk A/S, XL-protein GmbH
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
246
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Neuropeptide Y Receptor Type 2 Market Report Segments:
The global Neuropeptide Y Receptor Type 2 market is segmented on the basis of:
Types
XL-310, NN-9748, GT-002, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Obesity, Epilepsy, Type 2 Diabetes, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Gila Therapeutics Inc
- Novo Nordisk A/S
- XL-protein GmbH
Highlights of The Neuropeptide Y Receptor Type 2 Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- XL-310
- NN-9748
- GT-002
- Others
- By Application:
- Obesity
- Epilepsy
- Type 2 Diabetes
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Neuropeptide Y Receptor Type 2 Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Neuropeptide Y receptor type 2 is a protein that binds to neuropeptides, including neurotensin. Neurotensin is a hormone that regulates many processes in the body, including blood pressure and heart rate.
Some of the major companies in the neuropeptide y receptor type 2 market are Gila Therapeutics Inc, Novo Nordisk A/S, XL-protein GmbH.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Neuropeptide Y Receptor Type 2 Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Neuropeptide Y Receptor Type 2 Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Neuropeptide Y Receptor Type 2 Market - Supply Chain
4.5. Global Neuropeptide Y Receptor Type 2 Market Forecast
4.5.1. Neuropeptide Y Receptor Type 2 Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Neuropeptide Y Receptor Type 2 Market Size (000 Units) and Y-o-Y Growth
4.5.3. Neuropeptide Y Receptor Type 2 Market Absolute $ Opportunity
5. Global Neuropeptide Y Receptor Type 2 Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Neuropeptide Y Receptor Type 2 Market Size and Volume Forecast by Type
5.3.1. XL-310
5.3.2. NN-9748
5.3.3. GT-002
5.3.4. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Neuropeptide Y Receptor Type 2 Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Neuropeptide Y Receptor Type 2 Market Size and Volume Forecast by Application
6.3.1. Obesity
6.3.2. Epilepsy
6.3.3. Type 2 Diabetes
6.3.4. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Neuropeptide Y Receptor Type 2 Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Neuropeptide Y Receptor Type 2 Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Neuropeptide Y Receptor Type 2 Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Neuropeptide Y Receptor Type 2 Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Neuropeptide Y Receptor Type 2 Demand Share Forecast, 2019-2026
9. North America Neuropeptide Y Receptor Type 2 Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Neuropeptide Y Receptor Type 2 Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Neuropeptide Y Receptor Type 2 Market Size and Volume Forecast by Application
9.4.1. Obesity
9.4.2. Epilepsy
9.4.3. Type 2 Diabetes
9.4.4. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Neuropeptide Y Receptor Type 2 Market Size and Volume Forecast by Type
9.7.1. XL-310
9.7.2. NN-9748
9.7.3. GT-002
9.7.4. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Neuropeptide Y Receptor Type 2 Demand Share Forecast, 2019-2026
10. Latin America Neuropeptide Y Receptor Type 2 Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Neuropeptide Y Receptor Type 2 Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Neuropeptide Y Receptor Type 2 Market Size and Volume Forecast by Application
10.4.1. Obesity
10.4.2. Epilepsy
10.4.3. Type 2 Diabetes
10.4.4. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Neuropeptide Y Receptor Type 2 Market Size and Volume Forecast by Type
10.7.1. XL-310
10.7.2. NN-9748
10.7.3. GT-002
10.7.4. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Neuropeptide Y Receptor Type 2 Demand Share Forecast, 2019-2026
11. Europe Neuropeptide Y Receptor Type 2 Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Neuropeptide Y Receptor Type 2 Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Neuropeptide Y Receptor Type 2 Market Size and Volume Forecast by Application
11.4.1. Obesity
11.4.2. Epilepsy
11.4.3. Type 2 Diabetes
11.4.4. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Neuropeptide Y Receptor Type 2 Market Size and Volume Forecast by Type
11.7.1. XL-310
11.7.2. NN-9748
11.7.3. GT-002
11.7.4. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Neuropeptide Y Receptor Type 2 Demand Share, 2019-2026
12. Asia Pacific Neuropeptide Y Receptor Type 2 Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Neuropeptide Y Receptor Type 2 Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Neuropeptide Y Receptor Type 2 Market Size and Volume Forecast by Application
12.4.1. Obesity
12.4.2. Epilepsy
12.4.3. Type 2 Diabetes
12.4.4. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Neuropeptide Y Receptor Type 2 Market Size and Volume Forecast by Type
12.7.1. XL-310
12.7.2. NN-9748
12.7.3. GT-002
12.7.4. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Neuropeptide Y Receptor Type 2 Demand Share, 2019-2026
13. Middle East & Africa Neuropeptide Y Receptor Type 2 Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Neuropeptide Y Receptor Type 2 Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Neuropeptide Y Receptor Type 2 Market Size and Volume Forecast by Application
13.4.1. Obesity
13.4.2. Epilepsy
13.4.3. Type 2 Diabetes
13.4.4. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Neuropeptide Y Receptor Type 2 Market Size and Volume Forecast by Type
13.7.1. XL-310
13.7.2. NN-9748
13.7.3. GT-002
13.7.4. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Neuropeptide Y Receptor Type 2 Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Neuropeptide Y Receptor Type 2 Market: Market Share Analysis
14.2. Neuropeptide Y Receptor Type 2 Distributors and Customers
14.3. Neuropeptide Y Receptor Type 2 Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Gila Therapeutics Inc
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Novo Nordisk A/S
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. XL-protein GmbH
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. COMPANY4
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. COMPANY5
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
